TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24721334

Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) intervention (n=24) consisting of 1 week of therapist-supervised practices of daily tasks using SR of one's own performance (five 1-h sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Functional rehabilitation (control; n=20) intervention practicing the same daily tasks with a therapist's demonstration and guidance
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) intervention
Number of subjects: 44
Study: 22050871

Group type: EXPERIMENTAL
Intervention: Whole body hypothermia
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no hypothermia)
Number of subjects: 204
Study: 19173749

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 17499360

Group type: EXPERIMENTAL
Intervention: Succimer chelation therapy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 15479125

Group type: EXPERIMENTAL
Intervention: Lp(a) levels in women with aCAD(+), median 442 units/l, p<0.001
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Lp(a) levels in men with aCAD(+), median 274 units/l, p<0.001
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: HDL cholesterol levels in women with aCAD(+), 1.09 mmol/l, p<0.05
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Triglycerides in women with aCAD(+), 1.82 mmol/l, p<0.05
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Log(TG/HDL-C) in women with aCAD(+), higher than in women with aCAD(-)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Lp(a) levels in men with aCAD(-), median 138 units/l
Number of subjects: 530

Group type: COMPARATOR
Intervention: Lp(a) levels in women with aCAD(-), median 145 units/l
Number of subjects: 530
Study: 11463010

Group type: EXPERIMENTAL
Intervention: Continued oral anticoagulant therapy for 9 additional months
Number of subjects: 267

Group type: COMPARATOR
Intervention: Discontinuation of oral anticoagulant therapy after 3 months
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy during the initial 9 months after randomization
Number of subjects: 267

Group type: COMPARATOR
Intervention: Incidence of recurrence after discontinuation of treatment
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Incidence of recurrence after continued therapy
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Extended period of anticoagulant therapy
Number of subjects: 267
Study: 9750033

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (cisplatin + etoposide) plus radiotherapy followed by surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (cisplatin + etoposide) plus radiotherapy followed by additional radiotherapy and 2 additional cycles of chemotherapy
Number of subjects: 0
Study: 8032575

Group type: EXPERIMENTAL
Intervention: Euphylong (once-daily evening administration)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Euphylong (twice-daily administration)
Number of subjects: 18
Study: 3288432

Group type: EXPERIMENTAL
Intervention: Picenadol 25 mg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 31101545

Group type: EXPERIMENTAL
Intervention: BES (biodegradable polymer biolimus-eluting stent)
Number of subjects: 588

Group type: COMPARATOR
Intervention: EES (durable polymer everolimus-eluting stent)
Number of subjects: 588
Study: 28300856

Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate Lotion, 0.05% (HBP Lotion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate Cream, 0.05% (HBP Cream)
Number of subjects: 2
Study: 26429056

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (LR)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Open liver resection (OR)
Number of subjects: 131
Study: 23624701

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐surgical management (NSM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP) and Non‐surgical management (NSM)
Number of subjects: 0
Study: 21722582

Group type: EXPERIMENTAL
Intervention: Blinded continuous glucose monitoring (CGM)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Treatment periods of prandial insulins
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Run-in period
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 46
Study: 19703277

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with residents
Number of subjects: 18
Study: 17295560

Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Healthy weight intervention
Number of subjects: 355

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 355
Study: 16225489

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Pantoprazole 20 mg
Number of subjects: 2766
Study: 11899817

Group type: EXPERIMENTAL
Intervention: Intensive peloidobalneotherapy (daily procedures with 4-5 hours interval)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Peloidobalneotherapy (every other day)
Number of subjects: 124
Study: 10421182

Group type: EXPERIMENTAL
Intervention: Calf-thigh sequential pneumatic compression
Number of subjects: 149

Group type: COMPARATOR
Intervention: Plantar venous intermittent pneumatic compression
Number of subjects: 149
Study: 7588920

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ACE Inhibition (Captopril and Enalapril)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brain Natriuretic Peptide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atrial Natriuretic Peptide
Number of subjects: 36
Study: 2285255

Group type: EXPERIMENTAL
Intervention: IL-2 plus MLT (10 mg/day orally at 8.00 p.m.)
Number of subjects: 33

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 33
Study: 7013894

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 0.5 mg and heparin 5000 units subcutaneously, given 8-hourly in separate injection sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine/heparin-treated patients
Number of subjects: 0
Study: 31122901

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy (carboplatin and nab-paclitaxel)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 724
Study: 28538025

Group type: EXPERIMENTAL
Intervention: Stand Up Victoria intervention (12-month multicomponent workplace intervention)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 231
Study: 25148955

Group type: EXPERIMENTAL
Intervention: FVOO (30 mL, OOPC=961 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: VOO (30 mL, OOPC=289 mg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: FVOO (30 mL)
Number of subjects: 13
Study: 23511366

Group type: EXPERIMENTAL
Intervention: Left lateral position with 2 mL hyperbaric bupivacaine 0.5%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Modified lateral position with 2 mL hyperbaric bupivacaine 0.5%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sitting position with 2 mL hyperbaric bupivacaine 0.5%
Number of subjects: 75
Study: 20493642

Group type: COMPARATOR
Intervention: Radiotherapy to 70 Gy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Radiotherapy to 78 Gy
Number of subjects: 301

Group type: COMPARATOR
Intervention: Radiotherapy to 70 Gy for patients <70 years old
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Radiotherapy to 78 Gy for patients <70 years old
Number of subjects: 301

Group type: COMPARATOR
Intervention: Radiotherapy to 70 Gy for patients age 70 or older
Number of subjects: 301
Study: 19894328

Group type: EXPERIMENTAL
Intervention: Menatretenone 45 mg three times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menatretenone 45 mg twice a day
Number of subjects: 0
Study: 16735933

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of hormone therapy (group 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gradual discontinuation of hormone therapy (group 2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 91
Study: 15367481

Group type: EXPERIMENTAL
Intervention: Prescribing portrait only
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Educational module only
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both portrait and module
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 11343044

Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF), EleCare, followed for a median of 21 months (range 7 to 40 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF), EleCare
Number of subjects: 31
Study: 9475320

Group type: EXPERIMENTAL
Intervention: Dietary treatment for galactosaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro analysis of galactose or its close metabolites
Number of subjects: 0
Study: 7971582

Group type: EXPERIMENTAL
Intervention: Intratracheal Survanta (modified surfactant extracted from cow lung)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No surfactant treatment (control group)
Number of subjects: 34
Study: 2896076

Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg bid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30298024

Group type: EXPERIMENTAL
Intervention: Self-management intervention (priovi) in addition to care as usual (CAU)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Care as usual (CAU) alone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Self-management intervention (priovi)
Number of subjects: 108
Study: 28869842

Group type: EXPERIMENTAL
Intervention: Visualizing and Verbalizing for language comprehension and thinking (V/V); 4 hours per day, 10 weeks, 200 hours of face-to-face instruction
Number of subjects: 28
Study: 26354547

Group type: EXPERIMENTAL
Intervention: Low-FII diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-FII diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 20
Study: 23512892

Group type: EXPERIMENTAL
Intervention: Leptin administration via subcutaneous injection twice daily for 16 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo administration via subcutaneous injection twice daily for 16 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Leptin administration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 27
Study: 21811161

Group type: EXPERIMENTAL
Intervention: Standard-dose regimen (rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, all twice daily for 10 days)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Half-dose regimen (rabeprazole 10 mg, amoxicillin 500 mg, clarithromycin 250 mg, all twice daily for 10 days)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Standard-dose regimen
Number of subjects: 115

Group type: COMPARATOR
Intervention: Half-dose regimen
Number of subjects: 115
Study: 19364653

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 161

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 161
Study: 16280375

Group type: EXPERIMENTAL
Intervention: Educational programme (2 h lesson in each class; 2 h general session with patients and experts; first and second anonymous questionnaires)
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Control (questionnaires)
Number of subjects: 1776
Study: 15330320

Group type: EXPERIMENTAL
Intervention: amoxicillin/sulbactam (AMX-SUL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: azithromycin (AZM)
Number of subjects: 6

Group type: COMPARATOR
Intervention: doxycycline (DOX)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: levofloxacin (LVX)
Number of subjects: 6
Study: 11220426

Group type: EXPERIMENTAL
Intervention: 90 mg dextromethorphan (DM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9243350

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cyclosporin G (CSG)
Number of subjects: 11
Study: 8492715

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2856542

Group type: EXPERIMENTAL
Intervention: Low dose beclomethasone (200 micrograms bid)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose beclomethasone (1000 micrograms bid)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 28230581

Group type: EXPERIMENTAL
Intervention: Standardized software for handoff communication
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual handoff process
Number of subjects: 14
Study: 30921005

Group type: EXPERIMENTAL
Intervention: Lycopene supplements (15 mg capsules/day)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Green tea supplements (600 mg/day epigallocatechin gallate)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 28851296

Group type: EXPERIMENTAL
Intervention: Procalcitonin antibiotic prescribing guideline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 0
Study: 25565680

Group type: EXPERIMENTAL
Intervention: BPMED intervention (text message reminders)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 120
Study: 24199224

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 21371718

Group type: EXPERIMENTAL
Intervention: Open adjunctive ziprasidone (mean final dose 190 ± 92 mg/day) for mean of 79.2 ± 23.2 days
Number of subjects: 25
Study: 18288085

Group type: COMPARATOR
Intervention: 3 mg varenicline
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1 mg varenicline
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 15 and 30 mg amphetamine
Number of subjects: 45
Study: 17022368

Group type: EXPERIMENTAL
Intervention: Streblus asper leaf extract (SAE) solution (80 mg/ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 42
Study: 12878455

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normotensive pregnant women at 12-14 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normotensive pregnant women at 30-34 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High risk pregnancies
Number of subjects: 90
Study: 11520467

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 201
Study: 8987188

Group type: EXPERIMENTAL
Intervention: Avocado enriched diet (2000 Kcal, lipids 53% MFA 49 g saturated/unsaturated ratio 0.54)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Isocaloric control diet (MFA 34 g, saturated/unsaturated ratio 0.7)
Number of subjects: 67
Study: 2000786

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 6124083

Group type: EXPERIMENTAL
Intervention: Loud noise exposure (95 dBA or 100 dBA)
Number of subjects: 0
Study: 31006815

Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS) 50,000 IU
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Vitamin A Status (measured by plasma retinol)
Number of subjects: 306
Study: 28617530

Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B12
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-treatment group (no folic acid and vitamin B12)
Number of subjects: 90
Study: 26036418

Group type: EXPERIMENTAL
Intervention: Devitalized moss transplants
Number of subjects: 2

Group type: COMPARATOR
Intervention: Irrigated moss transplants
Number of subjects: 2
Study: 23306427

Group type: EXPERIMENTAL
Intervention: Combination therapy with 100 mg of rebamipide three times a day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Monotherapy with 100 mg celecoxib twice daily
Number of subjects: 75
Study: 21292169

Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg twice daily
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg once daily
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Alvimopan (both dosages)
Number of subjects: 518
Study: 19719843

Group type: EXPERIMENTAL
Intervention: Long protocol with rFSH and pre‐treatment with hCG (200 IU/day for 7 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Long protocol with rFSH (control group)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Long protocol with rFSH and pre‐treatment with hCG
Number of subjects: 2
Study: 17432347

Group type: EXPERIMENTAL
Intervention: Preservation or reconstruction of uncinate process during nasal sinus opening surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional functional endoscopic sinus surgery (FESS)
Number of subjects: 30
Study: 15226339

Group type: EXPERIMENTAL
Intervention: Urokinase every 2 weeks for 12 months
Number of subjects: 577

Group type: COMPARATOR
Intervention: Heparin every 2 weeks for 12 months
Number of subjects: 577
Study: 11520428

Group type: EXPERIMENTAL
Intervention: Garlic supplement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vegan diet
Number of subjects: 16
Study: 9517598

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 500 microg
Number of subjects: 306
Study: 7831624

Group type: EXPERIMENTAL
Intervention: salmon calcitonin nasal spray (200 IU every other day, n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: calcium alone (n = 22)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 44
Study: 3050006

Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy for 7 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31506734

Group type: EXPERIMENTAL
Intervention: Optimum Glide Path motion (OGP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous rotation (CR) with HyFlex EDM Glide Path Files
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual instrumentation with stainless steel K‐files (SS)
Number of subjects: 30
Study: 30252054

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14
Study: 27090586

Group type: EXPERIMENTAL
Intervention: Multiplanar reformatted method for estimating right-to-left ventricular ratios
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Axial method for estimating right-to-left ventricular ratios
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified Miller score for estimating thrombus burden
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Refined Miller method for estimating thrombus burden
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified Miller method for estimating thrombus burden
Number of subjects: 10
Study: 26071025

Group type: EXPERIMENTAL
Intervention: Low-intensity functional electrical stimulation (FES)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Natural sitting condition
Number of subjects: 15
Study: 23737323

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Topical nifedipine ointment (5 min twice daily for 4 weeks)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Topical nifedipine ointment
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS) and Topical nifedipine ointment
Number of subjects: 142
Study: 22078193

Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg for 3 days followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo for 3 days followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses
Number of subjects: 130
Study: 19930851

Group type: EXPERIMENTAL
Intervention: Intra-operative warming using a forced-air warmer with an upper body blanket (warming group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intra-operative warming (non-warming group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intra-operative warming using a forced-air warmer
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intra-operative warming
Number of subjects: 24
Study: 16779529

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 77
Study: 15040091

Group type: EXPERIMENTAL
Intervention: Domestic bambuterol capsule
Number of subjects: 20

Group type: COMPARATOR
Intervention: Imported bambuterol tablet
Number of subjects: 20
Study: 10890304

Group type: EXPERIMENTAL
Intervention: Extensive alcohol counseling
Number of subjects: 165

Group type: COMPARATOR
Intervention: Brief assessment followed by feedback of risky alcohol consumption
Number of subjects: 165
Study: 8636453

Group type: EXPERIMENTAL
Intervention: Topical application of metronidazole 25% dental gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subgingival scaling
Number of subjects: 30
Study: 1545086

Group type: EXPERIMENTAL
Intervention: Clean Room (CR) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Common sickroom (non-clean room)
Number of subjects: 30
Study: 6495025

Group type: EXPERIMENTAL
Intervention: Metrizamide myelography
Number of subjects: 122

Group type: COMPARATOR
Intervention: Computed tomography
Number of subjects: 122